Correction to: Clinical implications of prospective genomic profiling of metastatic breast cancer patients
Authors:
Courtney T. van Geelen, Peter Savas, Zhi Ling Teo, Stephen J. Luen, Chen-Fang Weng, Yi-An Ko, Keilly S. Kuykhoven, Franco Caramia, Roberto Salgado, Prudence A. Francis, Sarah-Jane Dawson, Stephen B. Fox, Andrew Fellowes, Sherene Loi
Correction to: Clinical implications of prospective genomic profiling of metastatic breast cancer patients
Authors
Courtney T. van Geelen Peter Savas Zhi Ling Teo Stephen J. Luen Chen-Fang Weng Yi-An Ko Keilly S. Kuykhoven Franco Caramia Roberto Salgado Prudence A. Francis Sarah-Jane Dawson Stephen B. Fox Andrew Fellowes Sherene Loi
Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.